Back Number 2013

Octoner 31, 2013
Third quarter of 2013:
Bayer continues positive business momentum

- Ongoing dynamic trend in Life Sciences; MaterialScience level with prior-year quarter
- New pharmaceutical products post excellent growth
- Group sales EUR 9,643 million (minus 0.2 percent; Fx & portfolio adj. plus 6.0 percent)
- EBIT shows 47.5 percent improvement to EUR 1,221 million
- EBITDA before special items moves 7.7 percent higher to EUR 1,984 million
- Net income advances by 42.1 percent to EUR 733 million
- Core earnings per share up 8.5 percent to EUR 1.27
- Group guidance for 2013 maintained
July 31, 2013
Second quarter of 2013:
Bayer: strong growth in Life Sciences

- HealthCare and CropScience post dynamic growth, MaterialScience weak
- New pharmaceutical products well above expectations
- Group sales rise 1.9 percent (Fx & portfolio adj. 4.6 percent) to EUR 10,360 million
- EBIT advances by 73.9 percent to EUR 1,287 million
- EBITDA before special items up by 1.2 percent to EUR 2,195 million
- Net income climbs 74.8 percent to EUR 841 million
- Core earnings per share up 6.2 percent to EUR 1.54
- Group outlook for 2013 maintained
April 25, 2013
1st quarter of 2013:
Bayer: Life Sciences off to a good start in anniversary year

- New pharmaceutical products spur growth at HealthCare, continuing strong development at CropScience, cost pressure at MaterialScience
- Group sales up 2.1 percent to EUR 10,266 million
- EBIT improves by 8.6 percent to EUR 1,771 million
- EBITDA before special items increased by 0.4 percent to EUR 2,453 million
- Net income rises 11.5 percent to EUR 1,160 million
- Gratifying development in Emerging Markets
- Group outlook for 2013 confirmed
April 3, 2013
New products create optimism for the future
Bayer: continuing growth momentum

- Sales reached 234.9 billion yen in 2012
- All subgroups maintained high level of sales
- CropScience expanded market share
- New Growth Strategy aims for 330 billion yen sales by 2017
February 28, 2013
New products create optimism for the future
Bayer: continuing growth momentum

- Group targets achieved in 2012 - sales and earnings before special items increase in all subgroups
- Sales increase by 8.8 percent to EUR 39,760 million
- EBIT EUR 3,960 million (minus 4.6 percent) - Net income EUR 2,446 million (minus 1.0 percent)
- Further accounting measures for legal claims
- EBITDA before special items rises by 8.8 percent to EUR 8,284 million
- Encouraging growth in the emerging markets
- Steady progress with innovation pipeline strengthens life-science businesses
- Forecast for anniversary year 2013: continuing record development

Special Interest

Media

Share Price/Index